The unmet need in rheumatology: Reports from the targeted therapies meeting 2017

Clinical Immunology

Volumn 186, Issue , 2018, Pages 87-93

  Winthrop, Kevin L ^a   Strand, Vibeke ^b   van der Heijde, Désirée ^c   Mease, Philip ^d   Crow, Mary ^e   Weinblatt, Michael ^f   Bathon, Joan ^g   Burmester, Gerd R ^h   Dougados, Maxime ⁱ   Kay, Johnathan ^j   Mariette, Xavier ^k   Van Vollenhoven, Ronald ^l   Sieper, Joachim ^h   Melchers, Fritz ^m,n   Breedfeld, Ferdinand C ^o   Kalden, Joachim ^p   Smolen, Josef S ^q   Furst, Daniel E ^r  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c LEIDEN UNIVERSITY   (Netherlands)

^d UNIVERSITY OF WASHINGTON   (United States)

^e HOSPITAL FOR SPECIAL SURGERY   (United States)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

^g Columbia University ^*  (United States)

^h CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

ⁱ Hôpital Cochin ^*  (France)

^j UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^k UNIVERSITÉ PARIS SACLAY   (France)

^l Amsterdam Rheumatology and Immunology Center   (Netherlands)

^m MAX PLANCK INSTITUTE FOR INFECTION BIOLOGY   (Germany)

ⁿ DEUTSCHES RHEUMA FORSCHUNGSZENTRUM   (Germany)

^o LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^p UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^q MEDICAL UNIVERSITY OF VIENNA   (Austria)

^r UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

Ankylosing spondylitis; Inflammatory myopathies; Psoriatic arthritis; Rheumatoid arthritis; Sj gren's syndrome; Spondyloarthritis; Systemic lupus erythematosus; Systemic sclerosis; Vasculitis

Indexed keywords

ANTIRHEUMATIC AGENT;

ARTICLE; BEHCET DISEASE; HUMAN; IMMUNOGLOBULIN G4 RELATED DISEASE; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; RHEUMATOLOGY; SJOEGREN SYNDROME; SPONDYLARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; TREATMENT RESPONSE; VASCULITIS; MEDICAL RESEARCH; METHODOLOGY; MOLECULARLY TARGETED THERAPY;

BIOMEDICAL RESEARCH; HUMANS; MOLECULAR TARGETED THERAPY; RESEARCH DESIGN; RHEUMATIC DISEASES; RHEUMATOLOGY;

EID: 85028377533     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2017.08.009     Document Type: Article

References (56)

1. Furst, D.E., et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012. Ann. Rheum. Dis. 72:Suppl. 2 (2013), ii2–34.
2. Singh, J.A., et al. 2015 American college of rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res. 68:1 (2016), 1–25.
3. Smolen, J.S., et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann. Rheum. Dis. 76:6 (2017), 960–977.
4. Gossec, L., et al. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann. Rheum. Dis. 75:3 (2016), 499–510.
5. Winthrop, K.L., et al. The unmet need in rheumatology: reports from the Targeted Therapies meeting 2016. Clin. Exp. Rheumatol. 34:4 Suppl. 98 (2016), 69–76.
6. Breedveld, F.C., et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 54:1 (2006), 26–37.
7. Cook, M.J., et al. Predictors and outcomes of sustained, intermittent or never achieving remission in patients with recent onset inflammatory polyarthritis: results from the Norfolk Arthritis Register. Rheumatology (Oxford) 55:9 (2016), 1601–1609.
8. Hopson, S., et al. Impact of out-of-pocket costs on prescription fills among new initiators of biologic therapies for rheumatoid arthritis. J. Manag. Care Spec. Pharm. 22:2 (2016), 122–130.
9. Ferriols-Lisart, R., Ferriols-Lisart, F., Dose modifications of anti-TNF drugs in rheumatoid arthritis patients under real-world settings: a systematic review. Rheumatol. Int. 35:7 (2015), 1193–1210.
10. Kiely, P.D., Biologic efficacy optimization-a step towards personalized medicine. Rheumatology (Oxford) 55:5 (2016), 780–788.
11. van der Meulen, T.A., et al. The microbiome systemic diseases connection. Oral Dis. 22:8 (2016), 719–734.
12. Marenzana, M., Vande Velde, G., Refine, reduce, replace: imaging of fibrosis and arthritis in animal models. Best Pract. Res. Clin. Rheumatol. 29:6 (2015), 715–740.
13. Dorner, T., et al. The changing landscape of biosimilars in rheumatology. Ann. Rheum. Dis. 75:6 (2016), 974–982.
14. Kay, J., Winthrop, K., Biosimilar switching: “to set a form upon desired change”. Nat. Rheumatol. Rev. 13:7 (2017), 391–392.
15. Orbai, A.M., Updating the Psoriatic Arthritis (PsA) core domain set: a report from the PsA workshop at OMERACT 2016. Feb 1. pii: jrheum.160904 J. Rheumatol., 2017, 10.3899/jrheum.160904 [Epub ahead of print].
16. Haroon, M., FitzGerald, O., Psoriatic arthritis: complexities, comorbidities and implications for the clinic. Expert. Rev. Clin. Immunol. 12:4 (2016), 405–416.
17. Sukhov, A., Adamopoulos, I.E., Maverakis, E., Interactions of the immune system with skin and bone tissue in psoriatic arthritis: a comprehensive review. Clin. Rev. Allergy Immunol. 51:1 (2016), 87–99.
18. Mease, P.J., Measures of psoriatic arthritis: Tender and Swollen Joint Assessment, Psoriasis Area and Severity Index (PASI), Nail Psoriasis Severity Index (NAPSI), Modified Nail Psoriasis Severity Index (mNAPSI), Mander/Newcastle Enthesitis Index (MEI), Leeds Enthesitis Index (LEI), Spondyloarthritis Research Consortium of Canada (SPARCC), Maastricht Ankylosing Spondylitis Enthesis Score (MASES), Leeds Dactylitis Index (LDI), Patient Global for Psoriatic Arthritis, Dermatology Life Quality Index (DLQI), Psoriatic Arthritis Quality of Life (PsAQOL), Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F), Psoriatic Arthritis Response Criteria (PsARC), Psoriatic Arthritis Joint Activity Index (PsAJAI), Disease Activity in Psoriatic Arthritis (DAPSA), and Composite Psoriatic Disease Activity Index (CPDAI). Arthritis Care Res. 63:Suppl. 11 (2011), S64–85.
19. Barnas, J.L., Ritchlin, C.T., Etiology and pathogenesis of psoriatic arthritis. Rheum. Dis. Clin. N. Am. 41:4 (2015), 643–663.
20. Mease, P.J., Armstrong, A.W., Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis. Drugs 74:4 (2014), 423–441.
21. Gill, T., et al. The intestinal microbiome in spondyloarthritis. Curr. Opin. Rheumatol. 27:4 (2015), 319–325.
22. Ogdie, A., Schwartzman, S., Husni, M.E., Recognizing and managing comorbidities in psoriatic arthritis. Curr. Opin. Rheumatol. 27:2 (2015), 118–126.
23. Mease, P.J., Weinblatt, M., Peloso, P.M., Chen, K., Li, Y., Mansikka, H.T., Khatri, A., Othman, A.A., Wishart, N., Liu, J., Padley, R.J., Safety and efficacy of ABT-122, a TNF and IL-17–targeted dual variable domain (DVD)–Ig™, in psoriatic arthritis patients with inadequate response to methotrexate: results from a phase 2 trial [abstract]. Arthritis Rheumatol., 68(Suppl. 10), 2016.
24. Cobo-Ibanez, T., et al. Multidisciplinary dermatology-rheumatology management for patients with moderate-to-severe psoriasis and psoriatic arthritis: a systematic review. Rheumatol. Int. 36:2 (2016), 221–229.
25. Velez, N.F., et al. Management of psoriasis and psoriatic arthritis in a combined dermatology and rheumatology clinic. Arch. Dermatol. Res. 304:1 (2012), 7–13.
26. Berteau, J.P., et al. Morphological and biomechanical analyses of the subchondral mineralized zone in human sacral facet joints: application to improved diagnosis of osteoarthritis. Clin. Anat. 28:4 (2015), 538–544.
27. Baeten, D., et al. Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis. N. Engl. J. Med. 373:26 (2015), 2534–2548.
28. Deodhar, A., et al. The term 'non-radiographic axial spondyloarthritis' is much more important to classify than to diagnose patients with axial spondyloarthritis. Ann. Rheum. Dis. 75:5 (2016), 791–794.
29. Mahajan, A., Herrmann, M., Munoz, L.E., Clearance deficiency and cell death pathways: a model for the pathogenesis of SLE. Front. Immunol., 7, 2016, 35.
30. Wu, Y.W., Tang, W., Zuo, J.P., Toll-like receptors: potential targets for lupus treatment. Acta Pharmacol. Sin. 36:12 (2015), 1395–1407.
31. Jordan, N., D'Cruz, D., Key issues in the management of patients with systemic lupus erythematosus: latest developments and clinical implications. Ther. Adv. Musculoskelet. Dis. 7:6 (2015), 234–246.
32. Blanco, P., Ueno, H., Schmitt, N., T follicular helper (Tfh) cells in lupus: activation and involvement in SLE pathogenesis. Eur. J. Immunol. 46:2 (2016), 281–290.
33. Wu, H., et al. Critical link between epigenetics and transcription factors in the induction of autoimmunity: a comprehensive review. Clin. Rev. Allergy Immunol. 50:3 (2016), 333–344.
34. Arbuckle, M.R., et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N. Engl. J. Med. 349:16 (2003), 1526–1533.
35. Aberle, T., et al. Clinical and serological features distinguish patients with incomplete lupus classification from systemic lupus erythematosus patients and controls. Arthritis Care Res. (Hoboken), 2017 Jan 24, 10.1002/acr.23201 [Epub ahead of print].
36. Lu, R., et al. Dysregulation of innate and adaptive serum mediators precedes systemic lupus erythematosus classification and improves prognostic accuracy of autoantibodies. J. Autoimmun. 74 (2016), 182–193.
37. Munroe, M.E., et al. Discerning risk of disease transition in relatives of systemic lupus erythematosus patients utilizing soluble mediators and clinical features. Arthritis Rheumatol. 69:3 (2017), 630–642.
38. Study of Anti-Malarials in Incomplete Lupus Erythematosus (SMILE). Retrieved from https://clinicaltrials.gov/ct2/show/NCT03030118?term=lupus+hydroxychloroquine&rank=2, 2017 (Identification No. NCT03030118).
39. Reddy, V., et al. B-cell depletion in SLE: clinical and trial experience with rituximab and ocrelizumab and implications for study design. Arthritis Res. Ther., 15(Suppl. 1), 2013, S2.
40. Furie, R., et al. Anifrolumab, an anti-interferon-alpha receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus. Arthritis Rheumatol. 69:2 (2017), 376–386.
41. Moallem, E., et al. A liposomal steroid nano-drug for treating systemic lupus erythematosus. Lupus 25:11 (2016), 1209–1216.
42. Mahieu, M., Yount, S., Ramsey-Goldman, R., Patient-reported outcomes in systemic lupus erythematosus. Rheum. Dis. Clin. N. Am. 42:2 (2016), 253–263.
43. Kasturi, S., et al. Validity and reliability of patient reported outcomes measurement information system computerized adaptive tests in systemic lupus erythematosus. J. Rheumatol. 44:7 (2017), 1024–1031.
44. Cappelli, L.C., et al. Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab. Ann. Rheum. Dis. 76:1 (2017), 43–50.
45. Johnson, D.B., et al. Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders. JAMA Oncol. 2:2 (2016), 234–240.
46. Lee, L., Gupta, M., Sahasranaman, S., Immune checkpoint inhibitors: an introduction to the next-generation cancer immunotherapy. J. Clin. Pharmacol. 56:2 (2016), 157–169.
47. Stasi, R., An overview of pharmacotherapy for anti-neutrophil cytoplasmic antibody-associated vasculitis. Drugs Today (Barc.) 46:12 (2010), 919–928.
48. Flint, S.M., McKinney, E.F., Smith, K.G., Emerging concepts in the pathogenesis of antineutrophil cytoplasmic antibody-associated vasculitis. Curr. Opin. Rheumatol. 27:2 (2015), 197–203.
49. Tomasson, G., Outcome measures for antineutrophil cytoplasmic antibody-associated vasculitis. Curr. Opin. Rheumatol. 27:1 (2015), 38–44.
50. Aydin, S.Z., Merkel, P.A., Direskeneli, H., Outcome measures for Takayasu's arteritis. Curr. Opin. Rheumatol. 27:1 (2015), 32–37.
51. Adler, S., Reichenbach, S., Kuchen, S., Wermelinger, F., Dan, D., Villiger, P.M., Seitz, M., Tocilizumab for the treatment of giant cell arteritis – a randomized placebo-controlled trial [abstract]. Arthritis Rheumatol., 67(Suppl. 10), 2015.
52. Langford, C.A., et al. A randomized, double-blind trial of abatacept (CTLA-4Ig) for the treatment of giant cell arteritis. Arthritis Rheumatol. 69:4 (2017), 837–845.
53. Hao, M., et al. Diagnostic value of serum IgG4 for IgG4-related disease: a PRISMA-compliant systematic review and meta-analysis. Medicine (Baltimore), 95(21), 2016, e3785.
54. Sekiguchi, H., et al. Immunoglobulin G4-related disease: retrospective analysis of 166 patients. Arthritis Rheumatol. 68:9 (2016), 2290–2299.
55. Nocturne, G., et al. Rheumatoid factor and disease activity are independent predictors of lymphoma in primary Sjogren's syndrome. Arthritis Rheumatol. 68:4 (2016), 977–985.
56. Fragkioudaki, S., Mavragani, C.P., Moutsopoulos, H.M., Predicting the risk for lymphoma development in Sjogren syndrome: an easy tool for clinical use. Medicine (Baltimore), 95(25), 2016, e3766.